Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer

PURPOSE: To investigate the safety, activity, and potential biomarkers of response to olaparib and carboplatin combination in sporadic triple negative breast cancer (TNBC). EXPERIMENTAL DESIGN: Metastatic or recurrent TNBC patients with no germline BRCA mutation or with BRCAPro scores <10% and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jung-Min, Hays, John L., Chiou, Victoria L., Annunziata, Christina M., Swisher, Elizabeth M., Harrell, Maria I., Yu, Minshu, Gordon, Nicolas, Sissung, Tristan M., Ji, Jiuping, Figg, William D., Minasian, Lori, Lipkowitz, Stanley, Wood, Bradford J., Doroshow, James, Kohn, Elise C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668030/
https://www.ncbi.nlm.nih.gov/pubmed/29108297
http://dx.doi.org/10.18632/oncotarget.16577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668030/
https://www.ncbi.nlm.nih.gov/pubmed/29108297
http://dx.doi.org/10.18632/oncotarget.16577

Ejemplares similares